About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

As Tax Breaks for Pfizer End, Jobs Disappear

By Jim Edwards | Nov 16, 2009

As Pfizer (PFE) reorganizes after its merger with Wyeth, municipalities are finding that the tax deals they once struck to keep the drug giant in town are having short-term advantages at best and, at worst, no effect at all. Pfizer must make 19,500 layoffs across its empire to make the merger work.

In St. Louis, Pfizer is cutting 600 of 1,000 jobs. The company had been given $2 million in tax breaks to retrain 1,000 workers, plus $2.5 million in “Quality Jobs” subsidies, as part of a 10-year of tax abatement. StlToday.com:

St. Louis County officials are considering canceling the remainder of $6.7 million in property tax abatement to Pfizer.

… Ed Bryant, a spokesman for Pfizer, said the company “would fully meet its legal obligations.”

It looks like St. Louis will cancel the remainder of that abatement:

“They have clearly not lived up to the 1,000-job commitment they made,” [Dennis Coleman, president and chief executive officer of the St. Louis County Economic Council,] said. “This is something we take very seriously.”

New London, Conn., discovered something similar. Despite a 10-year tax abatement for its site there, Pfizer is abandoning its plans for a vast new campus just as the break comes to an end. The Boston Globe:

Pfizer got a sweetheart deal from New London eight years ago, paying taxes on only 20 percent of its property’s assessed value, which came out to $1.2 million a year. But with the tax bill jumping to $6.1 million in 2012, and with Pfizer consolidating operations as a result of its acquisition of the pharmaceutical company Wyeth, the drug manufacturer decided to abandon its 750,000-square-foot complex in New London.

Pfizer also asked Kalamazoo, Mich., for a tax break earlier this year. The company will lay off 250 people in the town, but keep 3,400 at a manufacturing plant — a deal that has locals breathing a sigh of relief.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • Pfizer names top scientists as it shakes up research

    FierceBiotech - 308 days 12 hours 3 minutes ago

    Pfizer is making a prominent home for the scientists it is gaining in the $62 billion deal to buy Wyeth. The pharma giant says that once it has completed its merger with Wyeth it will break up R&D into two big pieces: one for traditional drug development and another for biotech therapies and vaccines. And each division will have its own chief...

  • Pfizes Wastes No Time Realizing Cost Efficiencies

    Seeking Alpha - 116 days 9 hours 11 minutes ago

    Ockham Research submits: The largest deal among drug makers in the last year was completed today as Pfizer PFE officially merged with Wyeth WYE. At the close of trading on Thursday, Wyeth was delisted from the NYSE. Pfizer has wasted no time in announcing some of its

  • Pfizer Wastes No Time Realizing Cost Efficiencies

    Seeking Alpha - 116 days 9 hours 11 minutes ago

    Ockham Research submits: The largest deal among drug makers in the last year was completed today as Pfizer PFE officially merged with Wyeth WYE. At the close of trading on Thursday, Wyeth was delisted from the NYSE. Pfizer has wasted no time in announcing some of its

  • Wyeth Merger Cripples Efficiency Drive at Pfizer

    BNET Pharma - 6 days 5 hours 29 minutes ago

    Pfizer (PFE)’s merger with Wyeth appears to have cost it dearly in terms of the merged company’s ability to generate it’s own revenues, according to its Q4 2009 earnings report. Pfizer showed $16.5 billion in revenue for the quarter, off $5.4 billion in sales, marketing and admin costs. Post-merger, Pfizer’s staff now only generate...

  • Pfizer's Talks to Buy Wyeth Move Forward

    New York Times - 382 days 9 hours 39 minutes ago

    Pfizer 's talks to acquire Wyeth , the drug company that makes the antidepressant Effexor, have advanced, bringing the two pharmaceuticals giants closer to a potential merger, people briefed on the matter told DealBook on Friday

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement